Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the Company’s wholly owned subsidiary, APL Healthcare Limited’s Unit I & III, an Orals (Tablets, Capsules and Soft gel Capsules) and Derma manufacturing facilities located at Jadcherla, Mahabub Nagar District, Telangana, which were inspected by the United States Food and Drug Administration from January 9 to January 18, 2023, have now been classified as Voluntary Action Indicated (VAI).
The above information is a part of company’s filings submitted to BSE.
